Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Effect of Omega-3 Polyunsaturated Fatty Acids on Lipid Metabolism in Patients With Metabolic Syndrome and NAFLD

V. Šmíd, K. Dvořák, P. Šedivý, V. Kosek, M. Leníček, M. Dezortová, J. Hajšlová, M. Hájek, L. Vítek, K. Bechyňská, R. Brůha

. 2022 ; 6 (6) : 1336-1349. [pub] 20220211

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018176

Grantová podpora
AZV 15-28745A Ministerstvo Zdravotnictví Ceské Republiky
DRO-IKEM00023001 Ministerstvo Zdravotnictví Ceské Republiky
RVO-VFN64165/2020 Ministerstvo Zdravotnictví Ceské Republiky

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. n-3 polyunsaturated fatty acids (n-3-PUFAs) have been reported to ameliorate the progression of NAFLD in experimental studies; however, clinical trials have yielded contradictory results. The aim of our study was to assess the effects of n-3-PUFA administration on lipid metabolism and the progression of NAFLD in patients with metabolic syndrome. Sixty patients with metabolic syndrome and NAFLD were randomized in a double-blind placebo-controlled trial (3.6 g/day n-3-PUFA vs. placebo). During the 1-year follow-up, the patients underwent periodic clinical and laboratory examinations, liver stiffness measurements, magnetic resonance spectroscopy of the liver, and plasma lipidomic analyses. After 12 months of n-3-PUFA administration, a significant decrease in serum GGT activity was recorded compared with the placebo group (2.03 ± 2.8 vs. 1.43 ± 1.6; P < 0.05). Although no significant changes in anthropometric parameters were recorded, a significant correlation between the reduction of liver fat after 12 months of treatment-and weight reduction-was observed; furthermore, this effect was clearly potentiated by n-3-PUFA treatment (P < 0.005). In addition, n-3-PUFA treatment resulted in substantial changes in the plasma lipidome, with n-3-PUFA-enriched triacylglycerols and phospholipids being the most expressed lipid signatures. Conclusion: Twelve months of n-3-PUFA treatment of patients with NAFLD patients was associated with a significant decrease in GGT activity, the liver fat reduction in those who reduced their weight, and beneficial changes in the plasma lipid profile.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018176
003      
CZ-PrNML
005      
20220804134612.0
007      
ta
008      
220720s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/hep4.1906 $2 doi
035    __
$a (PubMed)35147302
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Šmíd, Václav $u Fourth Department of Internal Medicine, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000286647918 $7 xx0227180
245    10
$a Effect of Omega-3 Polyunsaturated Fatty Acids on Lipid Metabolism in Patients With Metabolic Syndrome and NAFLD / $c V. Šmíd, K. Dvořák, P. Šedivý, V. Kosek, M. Leníček, M. Dezortová, J. Hajšlová, M. Hájek, L. Vítek, K. Bechyňská, R. Brůha
520    9_
$a Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. n-3 polyunsaturated fatty acids (n-3-PUFAs) have been reported to ameliorate the progression of NAFLD in experimental studies; however, clinical trials have yielded contradictory results. The aim of our study was to assess the effects of n-3-PUFA administration on lipid metabolism and the progression of NA $a Nonalcoholic fatty liver disease NAFLD is the most common chronic liver disease n 3 polyunsaturated fatty acids n 3 PUFAs have been reported to ameliorate the progression of NAFLD in experimental studies however clinical trials have yielded contradictory results The aim of our study was to assess the effects of n 3 PUFA administration on lipid metabolism and the progression of NAFLD in p $a Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. n-3 polyunsaturated fatty acids (n-3-PUFAs) have been reported to ameliorate the progression of NAFLD in experimental studies; however, clinical trials have yielded contradictory results. The aim of our study was to assess the effects of n-3-PUFA administration on lipid metabolism and the progression of NAFLD in patients with metabolic syndrome. Sixty patients with metabolic syndrome and NAFLD were randomized in a double-blind placebo-controlled trial (3.6 g/day n-3-PUFA vs. placebo). During the 1-year follow-up, the patients underwent periodic clinical and laboratory examinations, liver stiffness measurements, magnetic resonance spectroscopy of the liver, and plasma lipidomic analyses. After 12 months of n-3-PUFA administration, a significant decrease in serum GGT activity was recorded compared with the placebo group (2.03 ± 2.8 vs. 1.43 ± 1.6; P < 0.05). Although no significant changes in anthropometric parameters were recorded, a significant correlation between the reduction of liver fat after 12 months of treatment-and weight reduction-was observed; furthermore, this effect was clearly potentiated by n-3-PUFA treatment (P < 0.005). In addition, n-3-PUFA treatment resulted in substantial changes in the plasma lipidome, with n-3-PUFA-enriched triacylglycerols and phospholipids being the most expressed lipid signatures. Conclusion: Twelve months of n-3-PUFA treatment of patients with NAFLD patients was associated with a significant decrease in GGT activity, the liver fat reduction in those who reduced their weight, and beneficial changes in the plasma lipid profile.
650    12
$a omega-3 mastné kyseliny $x terapeutické užití $7 D015525
650    _2
$a lidé $7 D006801
650    _2
$a metabolismus lipidů $7 D050356
650    12
$a metabolický syndrom $x farmakoterapie $7 D024821
650    12
$a nealkoholová steatóza jater $x farmakoterapie $7 D065626
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Dvořák, Karel $u Fourth Department of Internal Medicine, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic
700    1_
$a Šedivý, Petr $u Department of Diagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Kosek, Vít $u Department of Food Analysis and Nutrition, University of Chemistry and Technology, Prague, Czech Republic
700    1_
$a Leníček, Martin $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic
700    1_
$a Dezortová, Monika $u Department of Diagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Hajšlová, Jana $u Department of Food Analysis and Nutrition, University of Chemistry and Technology, Prague, Czech Republic
700    1_
$a Hájek, Milan $u Department of Diagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Vítek, Libor $u Fourth Department of Internal Medicine, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000253180151 $7 xx0035071
700    1_
$a Bechyňská, Kamila $u Department of Food Analysis and Nutrition, University of Chemistry and Technology, Prague, Czech Republic
700    1_
$a Brůha, Radan $u Fourth Department of Internal Medicine, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000199244301 $7 xx0031692
773    0_
$w MED00196656 $t Hepatology communications $x 2471-254X $g Roč. 6, č. 6 (2022), s. 1336-1349
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35147302 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134606 $b ABA008
999    __
$a ok $b bmc $g 1821984 $s 1169419
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 6 $c 6 $d 1336-1349 $e 20220211 $i 2471-254X $m Hepatology communications $n Hepatol Commun $x MED00196656
GRA    __
$a AZV 15-28745A $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a DRO-IKEM00023001 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a RVO-VFN64165/2020 $p Ministerstvo Zdravotnictví Ceské Republiky
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace